Sanofi (SNY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of a subcutaneous version of Sarclisa, or isatuximab, combined with standard treatments for multiple myeloma.

The company said the recommendation covers use of the subcutaneous form across all indications currently approved for the intravenous formulation in the European Union, and is based on late-stage trial data showing that the subcutaneous version performed comparably to the intravenous form, supported by several additional studies.

A final decision from regulators is expected in the coming months, Sanofi said.

Shares of Sanofi were up 2% pre-bell Friday.